A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer (bHERt-2).
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2014
At a glance
- Drugs Trastuzumab (Primary)
- Indications Brain metastases; Breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2012 Planned End Date changed from 1 Jun 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.